Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharmalot Ed Silverman

Pharmalittle: Detailed data on Alzheimer’s drug hold up to scrutiny; Horizon in takeover talks with three pharma giants

A drug co-developed by Sanofi is highly effective in treating the sometimes lethal disease called sleeping sickness.

Read The Story

In the Lab Megan Molteni

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

Pharmalot Ed Silverman

‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Biotech Matthew Herper

Former Merck CEO: Democracy and the drug industry are both in danger

Health Angus Chen

Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells

All Coverage

Pharmalot Ed Silverman

Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

Pharmalot Ed Silverman

Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy

Pharmalot Andrew Joseph

Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.

Pharmalot Damian Garde

Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO

Pharmalot Ed Silverman

Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval

Pharma Adam Feuerstein

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Pharma Hyacinth Empinado

Watch: This small-town pharmacy may be a model for more affordable drugs

Pharma Adam Feuerstein

Pfizer CEO says Covid vaccine will remain ‘free for all Americans,’ overlooking indirect costs

Pharmalot Ed Silverman

Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

Pharmalot Ed Silverman

Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs

Pharmalot Ed Silverman

Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’

First Opinion Anup Srivastava, Rong Zhao and Ge Bai

The conundrum of biopharma investing: low rewards and high risks — but a big social benefit

Pharmalot Ed Silverman

Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

Pharmalot Ed Silverman

Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis

Pharmalot Ed Silverman

Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process

Pharmalot Ed Silverman

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

Pharmalot Ed Silverman

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

Pharmalot Ed Silverman

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

Pharmalot Ed Silverman

Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.

Pharmalot Ed Silverman

Pharma

Pharmalittle: Detailed data on Alzheimer’s drug hold up to scrutiny; Horizon in takeover talks with three pharma giants

On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues

‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Former Merck CEO: Democracy and the drug industry are both in danger

Q&A: Siddhartha Mukherjee on the rapid pace of cancer research and ‘luminous’ life of cells

All Coverage

Pharmalittle: PhRMA trade group is losing its edge; Eisai CEO tries to silence critics of Alzheimer’s drug

Pharmalittle: Second clinical trial death may be linked to Eisai-Biogen Alzheimer’s drug; pharma presses the U.K. over ‘out of control’ levy

Pharmalittle: FDA approves first gene therapy for hemophilia B; pharma’s reputation slips in U.S.

Pharmalittle: GSK pulls a key blood-cancer drug off the market; Teva picks a new CEO

Pharmalittle: Type 1 diabetes drug is priced at $194,000; abortion opponents sue FDA over abortion pill approval

Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Watch: This small-town pharmacy may be a model for more affordable drugs

Pfizer CEO says Covid vaccine will remain ‘free for all Americans,’ overlooking indirect costs

Sales of antibiotics for food-producing animals dropped by nearly half in Europe over the past decade

Up and down the ladder: The latest comings and goings

Pharmalittle: WHO pandemic accord may force pharma to disclose prices; FDA OKs first therapy to delay type 1 diabetes

Pharmalittle: Big PBM keeps AbbVie’s Humira on formulary; Lilly CEO says fake tweet means there’s more to do on insulin costs

Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’

The conundrum of biopharma investing: low rewards and high risks — but a big social benefit

Pharmalittle: WHO scientist resigns amid shake-up; FDA considers over-the-counter naloxone

Walmart agrees to pay $3.1 billion in latest settlement stemming from the opioid crisis

Pharmalittle: Walmart to pay $3.1 billion to settle opioid claims; Indian Covid vaccine underwent troubling approval process

Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug

More drugmakers are expanding access in poorer countries, but progress continues to lag overall

‘A very worrying scenario’: Internal documents on India Covid-19 vaccine raise troubling questions about approval process

Pharmalittle: Roche Alzheimer’s drug fails in two studies; Indivior bets on addiction market with deal to buy Opiant

Up and down the ladder: The latest comings and goings

Pharmalittle: Lilly says fake Twitter account offered free insulin; AstraZeneca drops plans for Covid shot in the U.S.

Viatris executive is charged with insider trading scheme involving a friend and former colleague

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day